Actively Recruiting
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Led by International Consortium of Circulatory Assist Clinicians · Updated on 2025-12-16
150
Participants Needed
7
Research Sites
165 weeks
Total Duration
On this page
Sponsors
I
International Consortium of Circulatory Assist Clinicians
Lead Sponsor
A
Abbott
Collaborating Sponsor
AI-Summary
What this Trial Is About
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding and infection still remain a concern for clinicians, as well as a general lack of predictability towards adverse events in individuals with a dLVAD in place. There is a lack of description in the literature currently, regarding the interface between what the pump data provides and what is seen in clinical practice. There also is little known about the effects of what is provided in the pump data, in correlation to quality-of-life following dLVAD implantation. Therefore, the purpose of this study is to prospectively analyze normal and abnormal pump data through pump operations such as suction events, low flow alarms as well as other adventitious alarms, PI events and power cable disconnects greater than 20 seconds, from the HeartMate 3 ® dLVAD in order to clinically correlate this data to quality of life, frailty and other various medical conditions and adverse events as defined by the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). This will be achieved through two aims: 1) Evaluate the effectiveness of dLVAD pump operations data on clinical practice application (quality of life, frailty and various medical conditions, and adverse events such as GIB, RHF, infection, hypertension, arrhythmias and stroke); and 2) Evaluate correlations and relationships of longitudinal normal and abnormal dLVAD pump operations data, to demographic and clinical variables. This study is the first study to evaluate HeartMate 3 ® dLVAD pump operations data over time for effectiveness in the clinical practice.
CONDITIONS
Official Title
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Scheduled HeartMate 3 4 durable left ventricular assist device implantation
You will not qualify if you...
- Younger than 18 years of age
- Scheduled for a durable left ventricular assist device other than the HeartMate 3 4 device
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
UCSF
San Francisco, California, United States, 94143
Actively Recruiting
2
University of Florida
Gainesville, Florida, United States, 32611
Actively Recruiting
3
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
4
University of Kansas Medical Center
Kansas City, Kansas, United States, 66103
Active, Not Recruiting
5
Mayo Clinic-Rochester
Rochester, Minnesota, United States, 55902
Actively Recruiting
6
MUSC
Charleston, South Carolina, United States, 29425
Active, Not Recruiting
7
University of Utah
Salt Lake City, Utah, United States, 84112
Active, Not Recruiting
Research Team
S
Sarah E Schroeder, PhD MSN RN
CONTACT
T
Thomas Schloglhofer, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here